Core Viewpoint - Brainstorm Cell Therapeutics has secured a strategic private placement of $1 million, reflecting confidence in its operational momentum and the value of its NurOwn® platform [1] Financing Details - The financing is structured in two tranches, with the first payment of $500,000 already received and the second payment of $500,000 expected within 30 days [1] - The common stock was priced at $0.60 per share, a significant premium to the $0.54 closing price on February 9, 2026 [1] - The investment includes 120% warrant coverage for five years with an exercise price of $1.00 per share, indicating a nearly 100% premium to the recent market close [1] Company Strategy and Future Plans - The financing follows a period of strategic activity, including finalizing the Phase 3b trial design under a Special Protocol Assessment (SPA) and discussions regarding a Citizens Petition for Accelerated Approval [1] - Proceeds from the financing will support ongoing regulatory initiatives, prepayments for the upcoming Phase 3b trial of NurOwn® in ALS, and general corporate purposes [1] About NurOwn® Technology - NurOwn® technology involves autologous MSC-NTF cells, which are designed to deliver neurotrophic factors and immunomodulatory cytokines to target neurodegenerative diseases [1] - The platform has received Orphan Drug designation from both the FDA and the EMA, with a Phase 3 trial in ALS completed and a second Phase 3b trial set to launch [1] Company Background - Brainstorm Cell Therapeutics is focused on developing autologous adult stem cell therapies for neurodegenerative diseases, with a proprietary platform aimed at modulating neuroinflammation and promoting neuroprotection [1]

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for alleged violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a) and Rule 10b-5 [1] Summary by Relevant Sections - The lawsuit is focused on shareholders who purchased shares of PayPal during the specified class period [1] - Investors are encouraged to contact the DJS Law Group for potential lead plaintiff appointments [1]

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its CELLECTRA device and its impact on FDA filing timelines [1] Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from October 10, 2023, to December 26, 2025, with a deadline for participation set for April 7, 2026 [1] - Allegations include that Inovio's public statements were materially misleading due to manufacturing deficiencies that could delay the filing of a Biologics License Application (BLA) with the FDA [1] Group 2: Company Impact - The lawsuit claims that Inovio did not gather necessary evidence to support a priority review by the FDA, further compounding the misleading nature of its public statements [1] - Shareholders who purchased shares during the class period and suffered losses are encouraged to contact the DJS Law Group for potential recovery [1]

Core Viewpoint - Masonite International Corporation is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its share repurchase activities while in possession of acquisition offers from Owens Corning at higher prices [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from June 5, 2023, to February 8, 2024, with a deadline for participation set for April 7, 2026 [1]. - The complaint alleges that Masonite repurchased shares from investors while having knowledge of acquisition offers that would have significantly increased share prices [1]. Group 2: Investor Information - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this appointment is not necessary to participate in any recovery [1]. - The DJS Law Group specializes in securities class actions and aims to enhance investor returns through advocacy and counseling [1].

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its financial performance and internal controls during the class period from August 7, 2024, to February 9, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that Kyndryl's financial statements were misstated throughout the class period, leading to materially misleading public statements [1]. - The deadline for shareholders to participate in the lawsuit is April 13, 2026 [1]. - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments [1]. Group 2: Company Background - Kyndryl Holdings, Inc. is listed on the NYSE under the ticker symbol KD [1]. - The DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [1].

Core Viewpoint - REGENXBIO Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding the safety and efficacy of its RGX-111 product candidate, which led to a clinical hold by the FDA after a participant developed a tumor [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from February 9, 2022, to January 27, 2026, with a deadline for lead plaintiff appointments set for April 14, 2026 [1]. - The complaint alleges that REGENXBIO consistently made positive statements about RGX-111 while concealing adverse safety and efficacy information from investors [1]. Group 2: Impact on Shareholders - Shareholders who purchased RGNX shares during the class period are encouraged to contact the DJS Law Group regarding potential recovery of losses [1]. - The lawsuit highlights the potential financial impact on shareholders due to the misleading public statements made by the company [1].

Core Insights - The FDA has approved the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL), marking a significant advancement in treatment options [1][2] Group 1: FDA Approval and Treatment Significance - The approval is based on data from the Phase 3 AMPLIFY trial, establishing this regimen as the first all-oral, fixed-duration treatment for previously untreated CLL patients [1] - This combination offers patients the potential for time off treatment, enhancing long-term disease management [1][3] - The approval expands treatment choices for patients and healthcare providers, facilitating more targeted treatment decisions in CLL [1][3] Group 2: AMPLIFY Study Details - The AMPLIFY trial evaluated VENCLEXTA plus acalabrutinib against chemoimmunotherapy in previously untreated CLL patients without del(17p) or TP53 mutation [1] - Results indicated that the combination regimen reduced the risk of disease progression or death by 35% compared to chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.0038) [1] - Median progression-free survival (PFS) was not reached for the combination regimen, while it was 47.6 months for chemoimmunotherapy [1] Group 3: Safety Profile - The safety profile of the combination regimen aligns with the known safety profiles of each individual therapy [1] - Common adverse reactions (20%) include neutropenia, headache, diarrhea, musculoskeletal pain, and COVID-19 [1] - Serious adverse reactions (2%) include COVID-19 pneumonia (9%), second primary malignancies (2.7%), and neutropenia (2.1%) [1]

Core Viewpoint - Tetragon Financial Group Limited will host an investor conference call on March 6, 2026, to discuss its annual report and provide company updates [1] Group 1: Conference Call Details - The conference call is scheduled for March 6, 2026, at 15:00 GMT / 10:00 EST [1] - Investors can submit questions via email or online during the live presentation [1] - A replay of the call will be available for 30 days after the event [1] Group 2: Company Overview - Tetragon is a Guernsey closed-ended investment company with non-voting shares listed on Euronext Amsterdam and traded on the London Stock Exchange [1] - The investment manager for Tetragon is Tetragon Financial Management LP [1] - Tetragon's non-voting shares have restrictions on ownership by U.S. persons and are not intended for European retail investors [1]

Core Insights - The CEO Magazine has launched The Collection, an editorial platform aimed at curating and showcasing trusted businesses and services for global executives and high-net-worth individuals [1] - The Collection is designed to extend the magazine's editorial authority by providing a structured way for readers to discover high-quality businesses and experiences beyond traditional directories [1] Group 1: Platform Overview - The Collection is a long-term editorial initiative that applies the same standards used for profiling business leaders to identify outstanding organizations across various high-impact industries [1] - Each edition of The Collection focuses on specific categories, presenting a curated selection based on quality, reputation, and relevance to an international executive audience [1] - The platform emphasizes editorial integrity, as shortlisting is conducted through independent review without accepting applications, reinforcing its role as a credible endorsement [1] Group 2: Target Audience and Reach - The CEO Magazine has a brand reach of 13 million and a global readership comprising senior executives, business leaders, and high-net-worth individuals [1] - The Collection aims to become a recognized reference point for executives seeking trusted recommendations across business, lifestyle, and professional services [1] Group 3: Initial Focus Areas - Initial editions of The Collection will cover sectors such as luxury boutique accommodation, private wealth advisory, real estate, and executive health, where trust and quality are essential [1] - Inclusion in The Collection signifies third-party validation for businesses recognized through editorial assessment, enhancing their visibility and credibility [1]

Core Viewpoint - Select Water Solutions, Inc. has announced the pricing of a public offering of 13,725,491 shares of its Class A common stock at a price of $12.75 per share, with the intention to use the net proceeds for general corporate purposes, including water infrastructure projects, potential acquisitions, or debt repayment [1] Group 1: Offering Details - The public offering consists of 13,725,491 shares of Class A common stock priced at $12.75 per share [1] - The company has granted underwriters a 30-day option to purchase up to 2,058,824 additional shares at the public offering price [1] - The offering is expected to close on February 23, 2026, subject to customary closing conditions [1] Group 2: Use of Proceeds - Net proceeds from the offering will be used for general corporate purposes, including water infrastructure growth capital projects, potential acquisitions, or debt repayment under the sustainability-linked credit facility [1] Group 3: Underwriters - J.P. Morgan and BofA Securities are the lead book-running managers for the offering, with Citigroup, Piper Sandler, and Raymond James serving as joint book-running managers [1] - Additional co-managers include Johnson Rice & Company, MUFG, Northland Capital Markets, Roth Capital Partners, Seaport Global Securities, and Texas Capital Securities [1] Group 4: Company Overview - Select Water Solutions is a leading provider of sustainable water and chemical solutions to the energy industry, supported by critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities [1]